Growth Factors and Renal Cancer: Characterization and Therapeutic Implications

Overview

Journal World J Urol

Specialty Urology

Date 1995 Jan 1

PMID 9116755

Citations 4

Authors

J H Mydlo

Affiliations

Soon will be listed here.

Abstract

The heterogeneiety renal-cell carcinoma can lead to unpredictable behavior: the ability to achieve a large volume yet not metastasize, the ability to demonstrate late recurrence or spontaneous regression, or the capability to metastasize at a relatively small volume. One-third of all patients who undergo radical nephrectomy for presumed localized disease will eventually have metastasis. Since renal-cell carcinoma is not significantly radio- or chemosensitive, it is important to investigate new avenues for treatment of this tumor once it has spread, specifically at the molecular level. This review discusses the most recent work on growth factors and renal cancer and proposes possible modalities for treatment.

Citing Articles

The Ambivalent Role of miRNAs in Carcinogenesis: Involvement in Renal Cell Carcinoma and Their Clinical Applications.

Spadaccino F, Gigante M, Netti G, Rocchetti M, Franzin R, Gesualdo L Pharmaceuticals (Basel). 2021; 14(4).

PMID: 33918154 PMC: 8065760. DOI: 10.3390/ph14040322.

Establishment and characterization of a highly immunogenic human renal carcinoma cell line.

Prattichizzo C, Gigante M, Pontrelli P, Stella A, Rocchetti M, Gigante M Int J Oncol. 2016; 49(2):457-70.

PMID: 27278998 PMC: 4922831. DOI: 10.3892/ijo.2016.3544.

Two single nucleotide polymorphisms in the von Hippel-Lindau tumor suppressor gene in Taiwanese with renal cell carcinoma.

Wang W, Tsou M, Chen H, Hsu W, Lai Y BMC Res Notes. 2014; 7:638.

PMID: 25217002 PMC: 4168206. DOI: 10.1186/1756-0500-7-638.

Identification of proteins differentially expressed in the conventional renal cell carcinoma by proteomic analysis.

Hwa J, Park H, Jung J, Kam S, Park H, Kim C J Korean Med Sci. 2005; 20(3):450-5.

PMID: 15953868 PMC: 2782202. DOI: 10.3346/jkms.2005.20.3.450.

References

Mydlo J, Michaeli J, Cordon-Cardo C, Goldenberg A, Heston W, Fair W . Expression of transforming growth factor alpha and epidermal growth factor receptor messenger RNA in neoplastic and nonneoplastic human kidney tissue. Cancer Res. 1989; 49(12):3407-11. View

Koo A, Armstrong C, Bochner B, Shimabukuro T, Tso C, DeKernion J . Interleukin-6 and renal cell cancer: production, regulation, and growth effects. Cancer Immunol Immunother. 1992; 35(2):97-105. PMC: 11037957. DOI: 10.1007/BF01741856. View

Scher H, Heston W . Suramin as an archetypical compound in the development of growth factor antagonists for inhibition of genitourinary tumors. Cancer Treat Res. 1992; 59:131-51. DOI: 10.1007/978-1-4615-3502-7_12. View

La Rocca R, Stein C, Danesi R, Cooper M, Uhrich M, Myers C . A pilot study of suramin in the treatment of metastatic renal cell carcinoma. Cancer. 1991; 67(6):1509-13. DOI: 10.1002/1097-0142(19910315)67:6<1509::aid-cncr2820670608>3.0.co;2-f. View

Neal D, Sharples L, Smith K, Fennelly J, Hall R, Harris A . The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer. 1990; 65(7):1619-25. DOI: 10.1002/1097-0142(19900401)65:7<1619::aid-cncr2820650728>3.0.co;2-q. View

Klotz L, Kulkarni C, Mills G . End stage renal disease serum contains a specific renal cell growth factor. J Urol. 1991; 145(1):156-60. DOI: 10.1016/s0022-5347(17)38281-2. View

Nguyen M, Watanabe H, Budson A, Richie J, Hayes D, Folkman J . Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst. 1994; 86(5):356-61. DOI: 10.1093/jnci/86.5.356. View

Nakamoto T, Usui A, Oshima K, Ikemoto H, Mitani S, Usui T . Analysis of growth factors in renal cell carcinoma. Biochem Biophys Res Commun. 1988; 153(2):818-24. DOI: 10.1016/s0006-291x(88)81169-0. View

Pienta K, Isaacs W, Vindivich D, Coffey D . The effects of basic fibroblast growth factor and suramin on cell motility and growth of rat prostate cancer cells. J Urol. 1991; 145(1):199-202. DOI: 10.1016/s0022-5347(17)38291-5. View

10.

Watanabe H, Hori A, Seno M, Kozai Y, Igarashi K, Ichimori Y . A sensitive enzyme immunoassay for human basic fibroblast growth factor. Biochem Biophys Res Commun. 1991; 175(1):229-35. DOI: 10.1016/s0006-291x(05)81224-0. View

11.

Quesada J, Kurzrock R, Sherwin S, Gutterman J . Phase II studies of recombinant human interferon gamma in metastatic renal cell carcinoma. J Biol Response Mod. 1987; 6(1):20-7. View

12.

Bard R, Mydlo J, Freed S . Detection of tumor angiogenesis factor in adenocarcinoma of kidney. Urology. 1986; 27(5):447-50. DOI: 10.1016/0090-4295(86)90412-7. View

13.

Derynck R, Goeddel D, Ullrich A, Gutterman J, Williams R, Bringman T . Synthesis of messenger RNAs for transforming growth factors alpha and beta and the epidermal growth factor receptor by human tumors. Cancer Res. 1987; 47(3):707-12. View

14.

Chang S, Yu D, Sherwood E, Kozlowski J, Lee C . Inhibitory effects of suramin on a human renal cell carcinoma line, causing nephrogenic hepatic dysfunction. J Urol. 1992; 147(4):1147-50. DOI: 10.1016/s0022-5347(17)37505-5. View

15.

Kochevar G, Stanek J, Rucker E . Truncated fibronectin. An autologous growth-promoting substance secreted by renal carcinoma cells. Cancer. 1992; 69(9):2311-5. DOI: 10.1002/1097-0142(19920501)69:9<2311::aid-cncr2820690918>3.0.co;2-q. View

16.

Mydlo J, Zajac J, Macchia R . Conditioned media from a renal cell carcinoma cell line demonstrates the presence of basic fibroblast growth factor. J Urol. 1993; 150(3):997-1001. DOI: 10.1016/s0022-5347(17)35673-2. View

17.

SARGENT E, Gomella L, Belldegrun A, Linehan W, Kasid A . Epidermal growth factor receptor gene expression in normal human kidney and renal cell carcinoma. J Urol. 1989; 142(5):1364-8. DOI: 10.1016/s0022-5347(17)39100-0. View

18.

Stadler W, Richards J, Vogelzang N . Serum interleukin-6 levels in metastatic renal cell cancer: correlation with survival but not an independent prognostic indicator. J Natl Cancer Inst. 1992; 84(23):1835-6. DOI: 10.1093/jnci/84.23.1835. View

19.

Yamaoka M, Yamamoto T, Ikeyama S, Sudo K, Fujita T . Angiogenesis inhibitor TNP-470 (AGM-1470) potently inhibits the tumor growth of hormone-independent human breast and prostate carcinoma cell lines. Cancer Res. 1993; 53(21):5233-6. View

20.

Wynder E, Mabuchi K, WHITMORE Jr W . Epidemiology of adenocarcinoma of the kidney. J Natl Cancer Inst. 1974; 53(6):1619-34. View